Fusion Antibodies (LON:FAB) Stock Jumps 14.8% – Here’s Why

Fusion Antibodies plc (LON:FAB) rose 14.8% on Wednesday. The company traded as high as GBX 6.70 and last traded at GBX 6.31. Approximately 888,120 shares were traded during mid-day trading, an increase of 97% from the average session volume of 451,622 shares. The stock had previously closed at GBX 5.50.

Fusion Antibodies Price Performance

The stock has a market cap of £7.72 million, a P/E ratio of -6.17 and a beta of 1.24. The business has a 50-day simple moving average of GBX 10.13 and a 200 day simple moving average of GBX 12.11. The company has a current ratio of 2.82, a quick ratio of 2.36 and a debt-to-equity ratio of 20.41.

Fusion Antibodies (LON:FAB) last announced its earnings results on Monday, September 14th. The company reported GBX (1.20) EPS for the quarter. Fusion Antibodies had a negative net margin of 54.45% and a negative return on equity of 97.87%. On average, analysts forecast that Fusion Antibodies plc will post -130.00 earnings per share for the current year.

Fusion Antibodies Company Profile

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.